Preclinical studies of PROTACs in hematological malignancies

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013222" target="_blank" >RIV/00023736:_____/21:00013222 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.2174/1871529X21666210308111546" target="_blank" >https://doi.org/10.2174/1871529X21666210308111546</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1871529X21666210308111546" target="_blank" >10.2174/1871529X21666210308111546</a>

Result language
angličtina
Original language name
Preclinical studies of PROTACs in hematological malignancies
Original language description
Incorrectly expressed or mutated proteins associated with hematologic malignancies have been generally targeted by chemotherapy using small-molecule inhibitors or monoclonal antibodies. But the majority of these intracellular proteins are without active sites and antigens. PROTACs, proteolysis targeting chimeras, are bifunctional molecules designed to polyubiquitinate and degrade specific pathological proteins of interest (POIs) by hijacking the activity of E3-ubiquitin ligases for POI polyubiquitination and subsequent degradation by the proteasome.
Czech name
—
Czech description
—

Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)